Search

Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years.

… Wednesday, September 27, 2006 Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years. The 561 prostate

Memorial Sloan Kettering attained Magnet recognition for the second time, a testament to our continued dedication to high-quality nursing practice.

… Wednesday, November 25, 2020 VIDEO | 03:09 2020 MSK Nurses Magnet Recognition Video Details On November 23, 2020, Memorial Sloan Kettering (MSK) attained Magnet recognition for the second time, a testament to our continued dedication to high-quality nursing practice. The American Nurses Credentialing

MSK’s Convocation and the Gerstner Sloan Kettering Graduate School of Biomedical Sciences Commencement celebrate the achievements of young scientists.

… Wednesday, June 10, 2015 Ruth Anne Franklin (left), Ming Li, Myoungjoo Kim Graduates Ruth Anne Franklin (left) and Myoungjoo Kim with their mentor, immunologist Ming Li 2015 graduates Graduates of GSK and a joint program between Weill Cornell Medical College and the Sloan Kettering Institute with their

Get to know Abby Hawk, who got a tattoo of Memorial Sloan Kettering after being treated there for neuroblastoma.

… Friday, September 10, 2021 VIDEO | 00:04 Abby Leaves Her Mark Abby's tattoo shows the latitude and longitude of Memorial Sloan Kettering Cancer Center and the quote "The comeback is always stronger than the setback." Video Details It was a bold request. A high school senior living outside Toledo named

A lifelong smoker overcomes discomfort over what a lung cancer imaging test might reveal. She hopes her experience helps reduce the stigma for others who smoke.

… Thursday, September 19, 2024 Marylou Capes-Platt knew she was at an especially high risk for lung cancer . She had been a heavy smoker for 45 years, starting in her teens and continuing through a decades-long career in the music industry and as a writer and editor. She finally quit in 2007. But the threat

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

… Tuesday, April 30, 2013 Summary Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide. Targeted therapies hold promise for the treatment of many types of cancer. But a common predicament is that in many patients

The initiative lays the groundwork for speedier cancer drug approvals in both the United States and China.

… Tuesday, December 22, 2020 Summary The 3rd annual MSK-CTONG Symposium virtually brought together leading medical experts, including academic physicians, scientific leadership from pharmaceutical and biotechnology industries, as well as government regulators, to discuss US-China and international clinical

该计划为中美两国加快批准抗癌药物奠定了基础。

… Tuesday, December 22, 2020 总结 第 3 届年度 MSK-CTONG 研讨会通过线上的方式汇集了顶尖医学领域专家，包括学术性医师、来自制药和生物技术行业的科学带头人以及政府监管机构专家，共同探讨中美及国际临床试验。MSK 斯隆首席医生 Lisa DeAngelis 重申了 MSK 斯隆致力于支持和促进 MSK-CTONG 合作的机构承诺。澳大利亚第 26 任总理、亚洲学会第八届总裁兼 CEO 陆克文 (Kevin Rudd) 以英文和普通话发表了主题演讲，强调了中美合作共同抗击癌症的重要性。来自美国食品药品监督管理局 (FDA) 的 Richard Pazdur 博士和

Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce Eileen M. O’Reilly, MD; Howard I. Scher, MD; and Deb Schrag, MD, MPH, have been elected to the 11th class of Giants of Cancer Care® for their contributions to gastrointestinal cancer care, genitourinary cancer care, and prevention and care delivery respectively.

… Thursday, May 4, 2023 Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce Eileen M. O’Reilly, MD ; Howard I. Scher, MD ; and Deb Schrag, MD, MPH , have been elected to the 11 th class of Giants of Cancer Care® for their contributions to gastrointestinal cancer care, genitourinary cancer

MSK researchers and collaborators have developed a new type of CAR T cell designed to attack a cell surface protein called uPAR — allowing them to target both tumors and cancer-supporting cells in the tumor microenvironment.

… Monday, March 30, 2026 Chimeric antigen receptor T-cell therapy — CAR T for short — has been a major advance in treating blood cancers like leukemia and lymphoma. But the immunotherapy has struggled against solid tumors for two main reasons: tumor cells often don’t share one consistent surface target